The Grünenthal Group
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.
We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.
New Chief Executive Officer Grünenthal Group
Gabriel Baertschi follows Eric-Paul Pâques as CEO as of
The Grünenthal Group announces that Gabriel Baertschi has taken office as new CEO of the Grünenthal Group, The company’s Supervisory Board had named Gabriel Baertschi to become Grünenthal’s new Chief Executive Officer in June 2016. Gabriel Baertschi is joining Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where in his last appointment he served as country president for Japan.
Gabriel Baertschi has more than 20 years of international experience in the pharmaceutical industry, and succeeds Prof. Dr. Eric-Paul Pâques who retires at the end of 2016 after 23 years at Grünenthal.